Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region
European Journal of Cancer（2021）
摘要
Image 1
更多查看译文
关键词
Castration-resistant prostate cancer,Prostate cancer,Urological cancers,Antiandrogen therapy,Enzalutamide
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要